Nivolumab (Opdivo) Concentrate for Infusion from Japan
Nivolumab is a human monoclonal antibody PD-1 inhibitor for melanoma and lung cancer immunotherapy. Classified in HTS 3002.15.00.11 as it directly regulates immunological processes via checkpoint inhibition, in measured retail vials.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Provide PD-1 binding assay data; ensure oncology-specific FDA pathways
• Use validated cold chain with data loggers for immunotherapy stability